Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark

India’s trade margin rationalization policy changed how prices could be set for 137 non-scheduled cancer medicines. It placed a limit on trade margins across parts of the supply chain. The goal was to reduce excessive differences between procurement costs and patient prices. However, health groups say it did not create comprehensive, cost-based price controls.

The effect was especially visible for some generic brands. Palbociclib sold as Palbopro 125 mg fell from ₹40,421 to ₹2,720. Thiotepa sold as Samtepa 100 mg dropped from ₹80,072 to ₹7,150. These reductions show how large some earlier markups had been. Yet Jan Swasthya Abhiyan India says the formula still permits a 42.8% markup over stockist prices in direct hospital sales.

The policy therefore offers immediate relief for certain medicines but leaves important gaps. Patented therapies and imported innovator brands were not reduced. Experts want permanent statutory margin caps, independent verification, supply-chain audits, and broader public cancer-care infrastructure.

The reductions were dramatic. Palbociclib, sold under the generic brand Palbopro 125 mg, fell from ₹40,421 to ₹2,720. That is a reduction of ₹37,701, or roughly 93%. Thiotepa, sold as Samtepa 100 mg, dropped from ₹80,072 to ₹7,150. That is a reduction of ₹72,922, or roughly 91%.

These examples matter because they reveal the scale of earlier pricing differences. Jan Swasthya Abhiyan India said pharmaceutical companies, including major Indian generic manufacturers, had offered inflated trade margins while families faced unaffordable treatment costs. The new approach targeted trade margins in the distribution chain rather than setting prices from production costs.

The falls show that some patients may receive major savings. They also expose the policy’s limits. The group said a 42.8% markup over the stockist price can still be legitimized in direct hospital sales. Therefore, large reductions in selected generics may coexist with high prices elsewhere.

The policy left many high-cost patented therapies and imported innovator brands untouched. The article reports no price reduction for AstraZeneca’s Osimertinib and Selumetinib, MSD’s Pembrolizumab, Roche’s Phesgo, Alecensa and Avastin, and Janssen’s Daratumumab. These medicines remained at their earlier prices.

Other unchanged therapies included Astellas’s Gilteritinib and Padcev, Johnson & Johnson’s Rybrevant, Takeda’s Alunbrig, GSK’s Jemperli, Pfizer’s Lorbriqua, and AbbVie’s Imbruvica. This contrast is important. Some generic brands saw enormous price drops, while several newer or original therapies received no reduction under the notification.

The article links this outcome to the treatment of patient assistance programmes. Medicines supplied free through those programmes were excluded from the calculations. Public health groups therefore want the government to scrutinize company assistance schemes, apply controls across oncology therapies, and make access depend on medical need rather than commercial pricing.

The policy’s calculations did not include medicines supplied free under patient assistance programmes. The article gives this as the reason high-cost patented therapies and imported innovator brands were left untouched. Because those supplies were excluded, they did not contribute to the price or margin assessment used in the notification.

That mechanism had a clear practical effect. Prices remained unchanged for therapies including Osimertinib, Selumetinib, Pembrolizumab, Phesgo, Alecensa, Avastin, Daratumumab, Gilteritinib, Padcev, Rybrevant, Alunbrig, Jemperli, Lorbriqua, and Imbruvica. These examples include treatments from several major international manufacturers.

The article does not provide a separate explanation for why the programmes were excluded. It does show the consequence: the policy reduced prices for some generic brands but bypassed many expensive patented therapies. Health groups are demanding full scrutiny of assistance programmes and comprehensive controls covering all oncology medicines.

India’s anti-cancer market includes roughly 225 drugs and 500 formulations, with annual turnover of ₹12,500 crore. Statutory price ceilings covered 63 scheduled medicines listed in the National List of Essential Medicines 2022. Those medicines represented about ₹2,250 crore of the market.

The remaining market was much larger. More than ₹10,250 crore came from non-scheduled medicines outside statutory ceiling prices. The article says uncurbed margins in this segment increase patients’ out-of-pocket spending. The trade-margin policy targeted 137 non-scheduled anti-cancer drugs, but critics say it still allowed substantial markups rather than applying full cost-based controls.

This split explains why the policy may bring uneven relief. Some generic prices fell sharply, while several patented and imported therapies stayed unchanged. Public health groups want permanent margin caps across distribution channels, supply-chain data audits, and stronger public cancer infrastructure so treatment access is not determined by commercial pricing.

If distributors and hospitals continue applying high markups, patients may see little of the savings created by the price cuts. The policy can reduce a medicine’s listed price while still allowing a large gap between the stockist price and the final hospital bill. That matters because cancer treatment already creates substantial out-of-pocket costs.

Jan Swasthya Abhiyan India said the formula legitimizes a 42.8% markup over the stockist price in supply chains involving direct hospital sales. The Supreme Court cited an example of an injection bought for ₹11,000 and billed to hospital patients at ₹1.3 lakh. These figures show how supply-chain pricing can overwhelm a medicine’s underlying cost.

The likely result is uneven relief. Some generic medicines may become dramatically cheaper, but patients using other drugs may remain exposed to inflated bills. Health groups want permanent margin caps, independent verification, supply-chain audits, and expanded public cancer care to make savings reach patients.

Patents, generic competition, and supply-chain markups affect affordability at different points. A patent can protect an original therapy from direct generic competition, helping keep its price high. When generic competition exists, several manufacturers may sell equivalent medicines and create stronger pressure for lower prices. Distributors and hospitals can then add margins before the medicine reaches patients.

The article illustrates this pattern. Generic Palbociclib fell from ₹40,421 to ₹2,720, while Thiotepa dropped from ₹80,072 to ₹7,150. Yet patented therapies such as Osimertinib and Pembrolizumab saw no reduction. Jan Swasthya Abhiyan India also identified a possible 42.8% markup in direct hospital sales.

These factors can operate together. A medicine may be expensive because competition is limited, or because markups accumulate in the supply chain. The article supports cost-based controls, margin caps, transparent pricing, and audits. The broader explanation of how patents and competition work is established pharmaceutical-market knowledge, not fully detailed in the article.